FIGURE 5.

Exploration of the downstream pathway underlying the effect of cyclin‐dependent kinase‐like 3 (CDKL3) on glioma. A, Western blotting (WB) was used to verify the expression of epidermal growth factor receptor (EGFR), ribonucleotide reductase regulatory subunit M2 (RRM2), and PPM1A, which were selected from the differentially expressed genes in U87 cells. B, WB was used to detect the expression and phosphorylation of MAPK signaling pathway‐related proteins including ERK1/2, p‐ERK1/2, JNK, p‐JNK, P38, p‐P38, MEK, and p‐MEK in U87 and U251 cells. C, D, JNK pathway activator (anisomycin) was used to treat glioma cells transfected with normal control (shCtrl) or shCDKL3. Activation of the JNK signaling pathway by anisomycin was confirmed by WB (C) and the cells were subsequently subjected to detection of cell proliferation (D). Data are presented as mean ± SD. **P < .01, ***P < .001